secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-06-23T20:15:28+00:00
Accession:  0001104659-26-076822
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma gets FDA conditional approval of brand name QYLEKI for Netherton Syndrome candidate
--------------------------------------------------------------------------------

- FDA conditionally approved QYLEKI as proposed brand name for QRX003, an investigational treatment for Netherton Syndrome.
- No approved treatment currently exists; QRX003 could become the first if approved.
- Pivotal Phase 3 study expected to initiate in H2 2026; potential NDA filing in 2027.
- QRX003 holds Orphan Drug Designations in US, EU, Japan; Fast Track and Rare Pediatric Disease Designations from FDA.
- Positive clinical update from ongoing Pediatric Compassionate Use Program released June 16, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926076822/0001104659-26-076822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926076822/tm2618505d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-076822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer